Beyondspring (NASDAQ:BYSI) Upgraded by Zacks Investment Research to Hold

Beyondspring (NASDAQ:BYSI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, January 9th.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

A number of other research firms have also weighed in on BYSI. Maxim Group reissued a “buy” rating and issued a $52.00 target price on shares of Beyondspring in a research note on Friday, October 27th. HC Wainwright set a $60.00 target price on Beyondspring and gave the company a “buy” rating in a research note on Thursday, October 26th. Finally, Seaport Global Securities began coverage on Beyondspring in a research note on Tuesday, December 5th. They issued a “buy” rating and a $56.00 target price for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Beyondspring presently has an average rating of “Buy” and a consensus target price of $54.50.

Shares of Beyondspring (NASDAQ:BYSI) opened at $26.92 on Tuesday. Beyondspring has a 52 week low of $16.55 and a 52 week high of $48.49.

Beyondspring (NASDAQ:BYSI) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. sell-side analysts anticipate that Beyondspring will post -4.41 EPS for the current year.

An institutional investor recently bought a new position in Beyondspring stock. Tanaka Capital Management Inc. purchased a new stake in shares of Beyondspring Inc (NASDAQ:BYSI) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring comprises approximately 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned 0.10% of Beyondspring at the end of the most recent reporting period. 1.22% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at

Beyondspring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Get a free copy of the Zacks research report on Beyondspring (BYSI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with's FREE daily email newsletter.

Leave a Reply